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Abstract 
Cyclophosphamide (CPA) is an alkylating agent used for cancer 
chemotherapy, organ transplantation, and autoimmune disease 
treatment. Here, mRNA sequencing and high-resolution respirometry 
were performed to evaluate the alterations of Drosophila melanogaster 
gene expression fed with CPA under acute (0.1 mg/mL, for 24 h) and 
chronic (0.05 mg/mL, for 35 days) treatments. Differential expression 
analysis was performed using Cufflinks-Cuffdiff, DESeq2, and edgeR 
software. CPA affected genes are involved in several biological functions, 
including stress response and immune-related pathways, oxi-reduction 
and apoptotic processes, and cuticle and vitelline membrane formation. 
In particular, this is the first report of CPA-induced mitochondrial 
dysfunction caused by the downregulation of genes involved with 
mitochondria constituents. CPA treatment also changed the transcription 
pattern of transposable elements (TEs) from the gypsy and copia 
superfamilies. The results presented here provided evidence of CPA 
mitochondrial toxicity mechanisms and that CPA can modify TEs 
transcription in Drosophila flies. 
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